Immune and cardiovascular system network targets

The "Immune and cardiovascular system network targets" refers to the integrated web of molecular and cellular interactions that facilitate communication between the immune system and the cardiovascular apparatus (Swirski & Nahrendorf, 2018). This network is not a single molecular entity but a systems-level concept encompassing various cytokines (e.g., IL-1 beta, IL-6), chemokines, and signaling pathways that regulate vascular tone, inflammation, and tissue repair (Libby, 2021). Dysregulation of this network is a primary driver of chronic cardiovascular diseases, including atherosclerosis, where persistent immune activation leads to plaque progression and eventual rupture (Nian et al., 2004). Therapeutic strategies targeting this network, such as the use of canakinumab to inhibit IL-1 beta, have demonstrated that modulating specific immune nodes can significantly reduce the risk of major adverse cardiovascular events (Ridker et al., 2017). Because this represents a network rather than a single target, it is frequently analyzed using network pharmacology to identify key "hubs" that can be modulated to restore systemic balance (Zhang et al., 2021). For drug developers, this network provides a framework for identifying multi-target therapies that address the inflammatory underpinnings of heart disease while maintaining essential immune surveillance.

Other names

Cardio-immune networkImmune-cardiovascular crosstalkNeuro-immune-cardiovascular networkCardio-immunology targets

Modulation of the cardio-immune axis through the inhibition of pro-inflammatory cytokines and the stabilization of vascular endothelial function.